Pertussis vaccination programme for pregnant women update: vaccine coverage in England, July to September 2017

Health Protection Report
Volume 12 Number 1
5 January 2018
Pertussis vaccination programme for pregnant women update: vaccine coverage in England, July to September 2017

This report presents pertussis vaccine coverage in pregnant women in England for the period July to September 2017, updating previous data reported for April to June 2017 [1].

Following increased pertussis activity in all age groups, including infants under three months of age, and the declaration of a national pertussis outbreak in April 2012 [2] pertussis vaccine has been offered to pregnant women since 1 October 2012 [3]. The prenatal pertussis vaccination programme aims to minimise disease, hospitalisation and deaths in young infants, through intra-uterine transfer of maternal antibodies, until they can be actively protected by the routine infant programme with the first dose of pertussis vaccine scheduled at eight weeks of age [4]. In June 2014 the Joint Committee on Vaccination and Immunisation (JCVI) considered available data and, based on the high effectiveness and safety of the programme, advised it should continue for a further five years [5]. In February 2016 the JCVI considered new evidence demonstrating that vaccination earlier in pregnancy would increase opportunities during pregnancy for vaccination, without detrimentally affecting the protection afforded to the infant [6, 7]. Based on this, JCVI advised that vaccination should ideally be offered from gestational week 16, although for operational reasons, vaccination should be offered from around 20 weeks, on or after the foetal anomaly scan [8]. This advice was implemented from April 2016.

Reported pertussis activity was higher in 2016 than in any year between 2013 and 2015 but did not reach the overall peak levels recorded in 2012 [9]. The increase in 2016 was consistent with pre-existing cyclical trends with peaks in disease every 3 or 4 years. Cases have fallen in 2017 and from April to June 2017 were 17% lower than those reported in the same quarter of 2016 [10]. After the introduction of the maternal programme in 2012, reported incidence remained higher in all age groups from one year and older relative to years preceding the pre-2012 peak. In young infants under three months of age targeted by the programme, however, disease levels fell back to those observed before the 2012
peak and, whilst increasing in 2016, these young infant cases are still in line with those seen in earlier (pre-2012) peak years.

**Key points**

- Pertussis vaccine coverage in pregnant women averaged 69.8% across the quarter, 0.7% lower than coverage for the same period in 2016 but continuing at the higher levels seen since April 2016.

**Methods**

General practice (GP) level pertussis vaccine coverage data are automatically uploaded via participating GP IT suppliers to the ImmForm* website on a monthly basis.

ImmForm data are validated and analysed by PHE to check data completeness, identify and query any anomalous data and describe epidemiological trends.

Since April/May 2016 (implementation date varied by GP IT supplier) the following monthly data have been collected:

- **Denominator:** number of women who delivered in the survey month, excluding miscarriages and stillbirths, regardless of gestational age
- **Numerator:** number of women receiving pertussis vaccination between week 16 of pregnancy and delivery

For accurate denominators to be extracted from GP IT systems by the automated survey and precise coverage estimates to be calculated, it is important that the medical records of all women who have given birth have the following fields completed:

- the date of delivery
- the date of receipt of a pertussis-containing vaccine at or after week 16 of pregnancy, regardless of the setting where the vaccine was administered
- where relevant, fields indicating stillbirth or miscarriage

* ImmForm is the system used by Public Health England to record vaccine coverage data for some immunisation programmes and to provide vaccine ordering facilities for the NHS.
Participation and data quality

Data from the smallest IT supplier were unreliable and excluded for July to September 2017 whilst the supplier investigates. National GP practice participation remains high, between 93.3% (July) and 89.9% (September), but local prenatal pertussis coverage estimates for a small number of LTs, ATs and CCGs have reduced participation from GP practices, particularly in South West England.

Results

Pertussis vaccine coverage decreased from 71.1% in June to 69.3% July, and then gradually increased between July and September 2017 to 70.7% (Figure 1). Coverage between July and September 2017 was slightly (<1%) below coverage reported for the same period in 2016, but followed a similar upward trend.

During July to September, prenatal pertussis vaccine coverage by NHS England LT ranged from 56.8% (London, July) to 79.1% (Yorkshire and Humber, September) (Table1).

Figure 1. Monthly pertussis vaccination coverage (%) in pregnant women: England, 2013-2017

<table>
<thead>
<tr>
<th>Month</th>
<th>GP practices reporting 2017</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Feb</td>
<td>55</td>
<td>55</td>
<td>55</td>
<td>55</td>
<td>55</td>
<td>55</td>
</tr>
<tr>
<td>Mar</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>Apr</td>
<td>65</td>
<td>65</td>
<td>65</td>
<td>65</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>May</td>
<td>70</td>
<td>70</td>
<td>70</td>
<td>70</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>Jun</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>Jul</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Aug</td>
<td>85</td>
<td>85</td>
<td>85</td>
<td>85</td>
<td>85</td>
<td>85</td>
</tr>
<tr>
<td>Sep</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Oct</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Footnotes:
1. New IT specification implemented in March/April 2016 [11]; coverage reported prior to this date is likely to have been underestimated.
2. Women first offered pertussis vaccine from 20 weeks gestational age in April 2016 would have been expected to deliver in August 2016.
Discussion

Prenatal pertussis vaccine coverage remains high at around 70% and, although slightly below coverage reported in 2016, increased between July and September 2017 in line with previous years.

Factors that could have contributed to the overall increase in coverage observed since April 2016 were described in the April to September 2016 report [11]. Women who received vaccine from as early as 20 weeks were likely to be included in the data from August 2016 onwards for women delivering around the time of their due date. The longer period available for vaccination, including a greater opportunity for signposting and reminders, could be contributing to an increase in coverage.

National coverage estimates in the first half of 2016 were close to the 74% coverage estimates extracted from the Clinical Research Practice Datalink (CPRD) for the same period for the purpose of on-going estimation of vaccine effectiveness [12]. The CPRD is a sentinel primary care network that includes 510 English general practices, representing approximately 6% of the UK population [13].

A recently published study which used ImmForm GP level data to assess variation in maternal pertussis coverage found that patients’ ethnicity and deprivation were predictors of coverage which contributed to, but did not wholly account for, geographical variation in coverage in England [14]. Based on April 2014 to March 2015 pre-natal pertussis coverage data, and after adjusting for geography and deprivation, coverage was lowest in black-other and black-Caribbean women compared with White British women (−16.3% and −15.4%, respectively). Coverage decreased with increasing deprivation, and was 14% lower in the most deprived quintile compared with the least deprived [14].

Pertussis activity was high in 2016 and, although cases have been lower in the first half of 2017, unprotected young infants continue to be at risk of infection. GPs, practice nurses, obstetricians and midwives should continue to encourage pregnant women to receive the pertussis vaccine, ideally between weeks 20 and 32 of their pregnancy (but up to term) to optimise protection for their babies from birth [8]. Between July and September, pertussis vaccine coverage varied by more than 20% each month between Local. Identifying examples of good practice in areas achieving consistently high coverage for pertussis
vaccination during pregnancy and applying them to low coverage areas may help address this gap.

There are limitations to the data presented in this report. First, completeness of data is reliant on the recording of delivery dates in the mothers’ medical records and comparison of these data with national data on maternities [15], indicates that in 2016 these data represented about 65% of the population of pregnant women.

Second, the survey does not cover all GP practices in England and, GP practice participation fell below 90% in September. Amongst those GPs included there may be differential completeness of the recording of delivery dates. Coverage may be overestimated if women who have received the vaccine are more likely to have their delivery date recorded. Furthermore, women not registered with a GP (and therefore less likely to be having regular contact with the health service prior to delivery) will not be captured by this reporting system. Following the change in recommendation for eligibility of the vaccine around the time of the 20 week scan more vaccines may be delivered in maternity settings. This may increase vaccine coverage, but the extent to which doses administered in maternity settings are recorded in GP systems (used in this report) are unknown. Continued support in the delivery of this important programme has been sought from service providers (GP practices and maternity units), Screening and Immunisation Teams and Health Protection Teams. The continued high coverage reported here suggests the delivery of this programme is becoming better embedded. Screening and Immunisation Teams should continue to update service providers on the current epidemiology of the disease, the recent changes to and effectiveness of the vaccination programme, and the need to maintain and improve coverage achieved thus far. If coverage, and ultimately the impact of the programme itself, is to be accurately monitored, it is essential that GPs and practice nurses continue to ensure that vaccination and date of delivery are recorded in the patient’s GP record. In areas that have commissioned maternity units to offer pertussis vaccines in pregnancy, it is important that providers ensure doses of vaccines given to individual women are also communicated to the woman’s GP. Maternity units not offering pertussis vaccines to pregnant women should continue to discuss its importance, making use of available resources [16] and sign-post the woman to her GP to receive the vaccine.
Table 1. Monthly pertussis vaccination coverage (%) in pregnant women by NHS England Local Team: England, July to September 2017

<table>
<thead>
<tr>
<th>Local Team</th>
<th>Jul-17</th>
<th>Aug-17</th>
<th>Sep-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>London</td>
<td>56.8</td>
<td>58.1</td>
<td>58.1</td>
</tr>
<tr>
<td>Midlands and East (Central Midlands)</td>
<td>71.9</td>
<td>71.5</td>
<td>74.4</td>
</tr>
<tr>
<td>Midlands and East (East)</td>
<td>72.4</td>
<td>73.1</td>
<td>74.2</td>
</tr>
<tr>
<td>Midlands and East (North Midlands)</td>
<td>71.7</td>
<td>70.1</td>
<td>75.0</td>
</tr>
<tr>
<td>Midlands and East (West Midlands)</td>
<td>67.2</td>
<td>67.5</td>
<td>67.5</td>
</tr>
<tr>
<td>North (Cheshire and Merseyside)</td>
<td>72.0</td>
<td>73.0</td>
<td>77.2</td>
</tr>
<tr>
<td>North (Cumbria and North East)</td>
<td>74.6</td>
<td>74.5</td>
<td>74.6</td>
</tr>
<tr>
<td>North (Lancashire and Greater Manchester)</td>
<td>64.8</td>
<td>65.2</td>
<td>66.5</td>
</tr>
<tr>
<td>North (Yorkshire and Humber)</td>
<td>78.7</td>
<td>78.5</td>
<td>79.1</td>
</tr>
<tr>
<td>South (South Central)</td>
<td>72.9</td>
<td>72.4</td>
<td>72.6</td>
</tr>
<tr>
<td>South (South East)</td>
<td>72.5</td>
<td>73.0</td>
<td>72.2</td>
</tr>
<tr>
<td>South (South West)</td>
<td>70.4</td>
<td>69.4</td>
<td>70.8</td>
</tr>
<tr>
<td>South (Wessex)</td>
<td>72.2</td>
<td>72.8</td>
<td>72.7</td>
</tr>
<tr>
<td>ENGLAND</td>
<td>69.3</td>
<td>69.5</td>
<td>70.7</td>
</tr>
</tbody>
</table>

Monthly reported denominator

<table>
<thead>
<tr>
<th></th>
<th>Jul-17</th>
<th>Aug-17</th>
<th>Sep-17</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>33,981</td>
<td>33,676</td>
<td>32,325</td>
</tr>
</tbody>
</table>

Date of data extraction: 5 November 2017
References


2. A level 3 incident is the third of five levels of alert under the HPA’s Incident Reporting and Information System (IERP) according to which public health threats are classified and information flow to the relevant outbreak control team is coordinated. A level 3 incident is defined as one where the public health impact is significant across regional boundaries or nationally. An IERP level 3 incident was declared in April 2012 in response to the ongoing increased pertussis activity. *HPR*, 2012. **6**(15).

3. Department of Health press release, 28 September 2012. “Pregnant women to be offered whooping cough vaccination”.


5. Joint Committee on Vaccination and Immunisation minutes (2014).


7. Joint Committee on Vaccination and Immunisation minutes (February 2016).


About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

About Health Protection Report

Health Protection Report is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.


Queries relating to this document should be directed to:
Immunisation, Hepatitis and Blood Safety Department
National Infection Service, PHE Colindale,
61 Colindale Avenue, London NW9 5EQ.
pertussis@phe.gov.uk

© Crown copyright 2017
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, please visit: OGL or email: psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published:
PHE publications gateway number: 2017698

PHE supports the UN Sustainable Development Goals

Corporate member of Plain English Campaign
Committed to clearer communication
339

SUSTAINABLE DEVELOPMENT GOALS